ADVFN Logo

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Hot Features

Registration Strip Icon for default Register for Free to get streaming real-time quotes, interactive charts, live options flow, and more.

DEMG Deltex Medical Group Plc

0.1075
0.005 (4.88%)
28 Mar 2024 - Closed
Delayed by 15 minutes
Share Name Share Symbol Market Type Share ISIN Share Description
Deltex Medical Group Plc LSE:DEMG London Ordinary Share GB0059337583 ORD 0.01P
  Price Change % Change Share Price Bid Price Offer Price High Price Low Price Open Price Shares Traded Last Trade
  0.005 4.88% 0.1075 0.10 0.115 0.1075 0.1025 0.1025 15,396,070 13:12:53
Industry Sector Turnover Profit EPS - Basic PE Ratio Market Cap
Electromedical Apparatus 2.48M -1.15M -0.0006 -1.83 2.03M

Deltex Medical Group PLC New Monitor Sales in USA and UK (6093X)

23/02/2017 7:01am

UK Regulatory


Deltex Medical (LSE:DEMG)
Historical Stock Chart


From Mar 2019 to Mar 2024

Click Here for more Deltex Medical Charts.

TIDMDEMG

RNS Number : 6093X

Deltex Medical Group PLC

23 February 2017

23 February 2017

Deltex Medical Group plc

("Deltex Medical", "Deltex" or "the Company")

New monitor sales in USA and UK

Deltex Medical Group plc (AIM: DEMG), the global leader in Oesophageal Doppler Monitoring ("ODM"), is pleased to announce that it has received confirmation of monitor orders worth over GBP0.2m which, as indicated in the trading update announced on 18 January 2017 had moved into 2017 due to the rescheduling of capital allocations in a small number of hospitals.

The largest value sales contract is from the USA for six monitors from a seven hospital system in the Company's Great Lakes sales territory. The customer had originally planned to start implementation of ODM within its flagship hospital from April 2016 but, following delays in its procurement processes, has now decided to start implementation simultaneously in two additional hospitals.

The other major order is for 13 monitors from a consortium of NHS hospitals in the UK, comprising replacements for nine previously purchased monitors and four additional units.

Ewan Phillips, Deltex Medical's Chief Executive, commented:

"We are encouraged that we have been able to secure capital funding for our ODM monitors from major customers in both the USA and UK at a time of restricted capital budgets. The US sales contract means we can now move forward with supporting implementation of ODM in one of the most presitigious of the US platform accounts we announced in 2016."

For further information, please contact:-

 
 Deltex Medical Group            01243 774 837 
  plc                             investorinfo@deltexmedical.com 
 Nigel Keen, Chairman 
 Ewan Phillips, Chief 
  Executive 
 Jonathan Shaw, Group 
  Finance Director 
 
 Nominated Adviser & 
  Broker 
 Arden Partners plc              020 7614 5900 
 Chris Hardie 
 
   Financial Public Relations 
 IFC Advisory                    0203 053 8671 
 Tim Metcalfe 
  Graham Herring 
  Heather Armstrong 
 

Notes for Editors

Deltex Medical manufactures and markets haemodynamic monitoring technologies. Deltex Medical's ODM is the only technology to measure continuously blood flow in the central circulation in real time. Minimally invasive, easy to set up and quick to focus, the technology generates a low-frequency ultrasound signal, which is highly sensitive to changes in flow and measures them immediately. Deltex has been the only company in the enhanced haemodynamic space to build a robust and credible evidence base proving the clinical and economic benefits of its core technology, ODM. Randomised, controlled trials using Doppler have demonstrated that early fluid management intervention will reduce post-operative complications, reduce intensive care admissions, and reduce the length of hospital stay.

Company goal

ODM is increasingly recognised as a standard of care for patients undergoing major surgery and in critical care. The broader clinical area of haemodynamic management of which ODM is a core constituent is also now becoming widely accepted as an important major new medical modality. Consequently, the Company's focus is on maximising value from the opportunities presented as enhanced haemodynamic management is adopted into routine clinical practice around the world.

The Company is currently in the implementation phase of achieving this goal in a number of territories worldwide, operating directly in the UK, USA, Spain and Canada and through distribution arrangements in a further 30 countries.

There are over 3,200 monitors installed in hospitals around the world and around 700,000 patients have been treated to date using Deltex Medical's single patient disposable probes.

This information is provided by RNS

The company news service from the London Stock Exchange

END

CNTEANAAADKXEFF

(END) Dow Jones Newswires

February 23, 2017 02:01 ET (07:01 GMT)

1 Year Deltex Medical Chart

1 Year Deltex Medical Chart

1 Month Deltex Medical Chart

1 Month Deltex Medical Chart

Your Recent History

Delayed Upgrade Clock